Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Carrygenes Bioengineering LLC has 4 pending office actions in Biotechnology & Pharmaceuticals. The actions are distributed across 4 examiners and 4 art units, giving each matter a distinct examination context.
HUMPHRIES, NICHOLAS ADAM is the busiest examiner, with 1 pending action. The profile does not show examiner concentration, so prosecution planning should be organized by individual matter and technical record.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JUEDES, AMY E | 1 | 44.8% | +41.9% |
| HUMPHRIES, NICHOLAS ADAM | 1 | 34.2% | +76.6% |
| REGLAS, GILLIAN CHELSEA | 1 | 31.3% | +35.6% |
| LEITH, NANCY J | 1 | 74.7% | +43.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17582609 | Methods of Cell Renewal | REGLAS, GILLIAN CHELSEA | 19d overdue |
| 18685905 | Use Of Chemokine Receptors In Cellular Homing | HUMPHRIES, NICHOLAS ADAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17582609 | Methods of Cell Renewal | REGLAS, GILLIAN CHELSEA | 19d overdue |
| 17482307 | COMPOSITIONS AND METHODS FOR MONITORING IN REAL-TIME CONSTRUCTION AND BIOENGINEERING OF MAMMALIAN SYNTHETIC CHROMOSOMES | LEITH, NANCY J | 20d |
| 18685914 | Synthetic Chromosome Encoding Two Or More Chimeric Antigen Receptors Binding To Tumor Associated Antigens | JUEDES, AMY E | — |
| 18685905 | Use Of Chemokine Receptors In Cellular Homing | HUMPHRIES, NICHOLAS ADAM | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| 1631 | 1 |
| 1632 | 1 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18685914 | Synthetic Chromosome Encoding Two Or More Chimeric Antigen Receptors Binding To Tumor Associated Antigens | JUEDES, AMY E | 1644 | §103§112DP | Non-Final OA | — | Pending | Feb 23, 2024 |
| 18685905 | Use Of Chemokine Receptors In Cellular Homing | HUMPHRIES, NICHOLAS ADAM | 1631 | §102§103 | Non-Final OA | — | Pending | Feb 23, 2024 |
| 17582609 | Methods of Cell Renewal | REGLAS, GILLIAN CHELSEA | 1632 | §103§112 | Final Rejection | 19d overdue | Pending | Jan 24, 2022 |
| 17482307 | COMPOSITIONS AND METHODS FOR MONITORING IN REAL-TIME CONSTRUCTION AND BIOENGINEERING OF MAMMALIAN SYNTHETIC CHROMOSOMES | LEITH, NANCY J | 1636 | §102 | Final Rejection | 20d | Pending | Sep 22, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCarrygenes Bioengineering LLC has 4 pending office actions as of November 2026, spread across 4 art units and 4 examiners.
Amy E Juedes has the most, with 1 of Carrygenes Bioengineering LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.